The European Organization for Nuclear Research, known as CERN, is an intergovernmental organization that operates the largest particle physics laboratory in the world. Established in 1954, it is based in a northwestern suburb of Geneva, on the France–Switzerland border. It comprises 23 member states, and Israel is currently the only non-European country holding full membership. CERN is an official United Nations General Assembly observer.
The antiproton,
p
, is the antiparticle of the proton. Antiprotons are stable, but they are typically short-lived, since any collision with a proton will cause both particles to be annihilated in a burst of energy.
External beam radiotherapy (EBRT) is the most common form of radiotherapy. The patient sits or lies on a couch and an external source of ionizing radiation is pointed at a particular part of the body. In contrast to brachytherapy and unsealed source radiotherapy, in which the radiation source is inside the body, external beam radiotherapy directs the radiation at the tumour from outside the body. Orthovoltage ("superficial") X-rays are used for treating skin cancer and superficial structures. Megavoltage X-rays are used to treat deep-seated tumours, whereas megavoltage electron beams are typically used to treat superficial lesions extending to a depth of approximately 5 cm. X-rays and electron beams are by far the most widely used sources for external beam radiotherapy. A small number of centers operate experimental and pilot programs employing beams of heavier particles, particularly protons, owing to the rapid dropoff in absorbed dose beneath the depth of the target.
In medicine, proton therapy, or proton radiotherapy, is a type of particle therapy that uses a beam of protons to irradiate diseased tissue, most often to treat cancer. The chief advantage of proton therapy over other types of external beam radiotherapy is that the dose of protons is deposited over a narrow range of depth; hence in minimal entry, exit, or scattered radiation dose to healthy nearby tissues.
The Proton Synchrotron is a particle accelerator at CERN. It is CERN's first synchrotron, beginning its operation in 1959. For a brief period the PS was the world's highest energy particle accelerator. It has since served as a pre-accelerator for the Intersecting Storage Rings (ISR) and the Super Proton Synchrotron (SPS), and is currently part of the Large Hadron Collider (LHC) accelerator complex. In addition to protons, PS has accelerated alpha particles, oxygen and sulfur nuclei, electrons, positrons, and antiprotons.
The Bragg peak is a pronounced peak on the Bragg curve which plots the energy loss of ionizing radiation during its travel through matter. For protons, α-rays, and other ion rays, the peak occurs immediately before the particles come to rest. It is named after William Henry Bragg, who discovered it in 1903.
Fast neutron therapy utilizes high energy neutrons typically between 50 and 70 MeV to treat cancer. Most fast neutron therapy beams are produced by reactors, cyclotrons (d+Be) and linear accelerators. Neutron therapy is currently available in Germany, Russia, South Africa and the United States. In the United States, one treatment center is operational, in Seattle, Washington. The Seattle center uses a cyclotron which produces a proton beam impinging upon a beryllium target.
Particle therapy is a form of external beam radiotherapy using beams of energetic neutrons, protons, or other heavier positive ions for cancer treatment. The most common type of particle therapy as of August 2021 is proton therapy.
In radiobiology, the relative biological effectiveness is the ratio of biological effectiveness of one type of ionizing radiation relative to another, given the same amount of absorbed energy. The RBE is an empirical value that varies depending on the type of ionizing radiation, the energies involved, the biological effects being considered such as cell death, and the oxygen tension of the tissues or so-called oxygen effect.
The Antiproton Decelerator (AD) is a storage ring at the CERN laboratory near Geneva. It was built from the Antiproton Collector (AC) to be a successor to the Low Energy Antiproton Ring (LEAR) and started operation in the year 2000. Antiprotons are created by impinging a proton beam from the Proton Synchrotron on a metal target. The AD decelerates the resultant antiprotons to an energy of 5.3 MeV, which are then ejected to one of several connected experiments.
Atomic Spectroscopy and Collisions Using Slow Antiprotons (ASACUSA), AD-3, is an experiment at the Antiproton Decelerator (AD) at CERN. The experiment was proposed in 1997, started collecting data in 2002 by using the antiprotons beams from the AD, and will continue in future under the AD and ELENA decelerator facility.
The Antiproton Collector (AC) was part of the antiparticle factory at CERN designed to decelerate and store antimatter, to study the properties of antimatter and to create atoms of antihydrogen. It was built in 1986 around the existing Antiproton Accumulator (AA) to improve the antiproton production by a factor of 10. Together, the Antiproton Collector and the Antiproton Accumulator formed the so-called Antiproton Accumulator Complex (AAC).
AEgIS, AD-6, is an experiment at the Antiproton Decelerator facility at CERN. Its primary goal is to measure directly the effect of Earth's gravitational field on antihydrogen atoms with significant precision. Indirect bounds that assume the validity of, for example, the universality of free fall, the Weak Equivalence Principle or CPT symmetry also in the case of antimatter constrain an anomalous gravitational behavior to a level where only precision measurements can provide answers. Vice versa, antimatter experiments with sufficient precision are essential to validate these fundamental assumptions. AEgIS was originally proposed in 2007. Construction of the main apparatus was completed in 2012. Since 2014, two laser systems with tunable wavelengths and synchronized to the nanosecond for specific atomic excitation have been successfully commissioned.
GBAR, AD-7 experiment, is a multinational collaboration at the Antiproton Decelerator of CERN.
BASE, AD-8, is a multinational collaboration at the Antiproton Decelerator facility at CERN, Geneva. The goal of the Japanese and German BASE collaboration are high-precision investigations of the fundamental properties of the antiproton, namely the charge-to-mass ratio and the magnetic moment.
Michael Holzscheiter is a German-born professor at the University of New Mexico.
The Super Proton–Antiproton Synchrotron was a particle accelerator that operated at CERN from 1981 to 1991. To operate as a proton-antiproton collider the Super Proton Synchrotron (SPS) underwent substantial modifications, altering it from a one beam synchrotron to a two-beam collider. The main experiments at the accelerator were UA1 and UA2, where the W and Z boson were discovered in 1983. Carlo Rubbia and Simon van der Meer received the 1984 Nobel Prize in Physics for their decisive contribution to the SppS-project, which led to the discovery of the W and Z bosons. Other experiments conducted at the SppS were UA4, UA5 and UA8.
The TRAP experiment, also known as PS196, operated at the Proton Synchrotron facility of the Low Energy Antiproton Ring (LEAR) at CERN, Geneva, from 1985 to 1996. Its main goal was to compare the mass of an antiproton and a proton by trapping these particles in the penning traps. The TRAP collaboration also measured and compared the charge-to-mass ratios of antiproton and proton. Although the data-taking period ended in 1996, the analysis of datasets continued until 2006.
Extra Low ENergy Antiproton ring (ELENA) is a 30 m hexagonal storage ring that decelerates antiproton beams and delivers it to different AD experiments. It is situated inside the Antiproton Decelerator (AD) complex at CERN, Geneva. It is designed to further decelerate the antiproton beam coming from the Antiproton decelerator to an energy of 0.1 MeV for more precise measurements. The first beam circulated ELENA on 18 November 2016. The ring is expected to be fully operational by the end of the Long Shutdown 2 (LS2) in 2021.
The PUMA AD-9 experiment, at the Antiproton decelerator(AD) facility at CERN, Geneva, aims to look into the quantum interactions and annihilation processes between the antiprotons and the exotic slow-moving nuclei. PUMA's experimental goals require about one billion trapped antiprotons made by AD and ELENA to be transported to the ISOLDE-nuclear physics facility at CERN, which will supply the exotic nuclei. Antimatter has never been transported out of the AD facility before. Designing and building a trap for this transportation is the most challenging aspect for the PUMA collaboration.
